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ntracerebral hemorrhage (ICH) is a devastating, often fatal aftermath of stroke, but not generally amenable to treatment. [1] [2] [3] [4] [5] Emerging evidence has demonstrated that a strokeincited inflammatory cascade accelerates the formation of edema that surrounds hematomas, exacerbates the mass effect, and amplifies cell death. [4] [5] [6] [7] [8] After the ictus of ICH, blood components, including leukocytes, enter the brain and activate resident immune cells such as microglia. Subsequently, the infiltrating leukocytes and activated microglia boost the local production of proinflammatory factors. Together with cell death products, these catastrophic events amplify blood-brain barrier (BBB) disruption and destroy surrounding tissues, contributing to the development of perihematomal edema and the aggravated mass effect. [4] [5] [6] [7] [8] Therefore, brain inflammation has emerged as a major modifiable determinant now targeted for the development of novel ICH treatment. 7 As a critical component of the innate immune response to tissue injury, activation of the NOD-like receptor (NLR) NLRP3 (pyrin domain-containing protein 3) inflammasome leads to the cleavage of pro-IL (interleukin)-1β and pro-IL-18, as well as the subsequent release of biologically active IL-1β, IL-18, and other soluble mediators of inflammation. Recent evidence indicates that the ICH-induced activation of NLRP3 inflammasome can amplify the inflammatory response by releasing IL-1β and promoting neutrophil infiltration, thereby exacerbating brain edema. [9] [10] [11] Although previous studies provide mechanistic insights into NLRP3 as a promising target for restricting neuroinflammation and brain edema after ICH, they do not reflect clinical application because they involve either knockout models or use of pharmacological agents with limited potency and nonspecificity preceding ICH induction. [9] [10] [11] For clinical translation of prior experimental outcomes, preclinical testing in relevant models is mandatory. However, this option has been precluded by the lack of selective, potent NLRP3 inflammasome inhibitors. Now, we have devised a means of clinically relevant testing in an experimental ICH model by using MCC950, a selective, small-molecule NLRP3 inflammasome inhibitor with proven high potency in vitro and in vivo. We hypothesized that the pharmacological inhibition of NLRP3 inflammasome by administration of MCC950 would reduce inflammation and brain edema after ICH induced by the injection of autologous blood or collagenase.
Materials and Methods
Details of materials and experimental procedures are available from the online-only Data Supplement. This article adheres to the AHA Journals implementation of the Transparency and Openness Promotion Guidelines.
Animals
All animal experiments were approved by the Committee on the Ethics of Animal Experiments of Barrow Neurological Institute (Phoenix, AZ). All experiments were conducted in accordance with the National Institutes of Health (Bethesda, MD) Guide for the Care and Use of Laboratory Animals, and experiments were designed, performed, and reported according to the Animal Research: Reporting In Vivo Experiments guidelines (https:// www.nc3rs.org.uk/arrive-guidelines). Male C57BL/6 mice, 8 to 10 weeks old (20-25 g), were purchased from the Charles River Laboratories (Wilmington, MA). Female mice were not used to avoid any influences of sex steroids. All mice were housed in animal facilities under a standardized light-dark cycle and had free access to food and water. All animal surgeries were performed under anesthesia. Animals were randomly divided and assigned to experimental groups using a random number list generated by Microsoft Excel 2013.
Induction of ICH in Mice
ICH was induced in mice by injection of autologous blood or bacterial collagenase, as we previously described. [12] [13] [14] [15] [16] Details of ICH induction are given in the online-only Data Supplement.
Study Design and Drug Administration
A total of 302 male C57BL/6 mice (Charles River Laboratories), 8 to 10 weeks old, were used in this study. In autologous blood model, the mortality rate was 8.5% (20 of total 236) and exclusion rate was 16.7% (36 of total 236). In the collagenase model, the mortality rate was 13.3% (8 of total 60) and exclusion rate was 20% (12 of total 60). Six wild-type mice were used for in vitro experiments. MCC950 was dissolved in phosphate-buffered saline, as previously described. 17 Mice were given MCC950 at a dose of 10 mg/kg by intraperitoneal injection at indicated time points after ICH. Mice that received an equal volume of vehicle (phosphatebuffered saline) only were designated as controls. For the microglia depletion experiment, PLX3397 (Selleckchem, Houston, TX) was given by oral gavage at 40 mg/kg for 21 days before ICH induction. 16, 18 Drug treatment was continued until the end of experiments. Subsequently, anti-mouse Gr-1 monoclonal antibody (MAb-RB6-8C5; BioXcell, West Lebanon, NH) was given by intraperitoneal injection 1 day before and 1 day after ICH surgery at 250 µg per mouse to deplete Gr-1 + myeloid cells in vivo. 19, 20 In mice subjected to microglia depletion, no mice were excluded. More than 90% of microglia were depleted in mice receiving PLX3397. In mice subjected to Gr-1 + cell depletion, the exclusion rate was 5.9% (1 of total 17 because of death after surgery). The depletion of Gr-1 
Behavioral Assessment
Behavioral assessment was conducted at days 1 and 3 after ICH using the modified Neurological Severity Score together with corner-turning test to comprehensively evaluate motor, sensory, reflex, and balance functions, as previously described. [21] [22] [23] [24] The range of scores for modified Neurological Severity Score is from 0 to 18, defined as follows: a score of 13 to 18 indicates severe injury, 7 to 12 indicates moderate injury, and 1 to 6 indicates mild injury. Mice were given 1 point if they failed to perform a task. The corner-turning test assesses sensorimotor and postural asymmetries. In this process, each mouse is allowed to proceed into a corner with an angle of 30° and then must turn right or left. Each mouse repeated this procedure for 10×, with at least 30 s between trials. The percentage of right turns is then calculated.
Magnetic Resonance Imaging
Lesion volume and perihematomal edema were quantified at day 3 after ICH using a 7-T small animal MRI, as previously described. 13, 16 T2-weighted image sequence and susceptibility-weighted image sequence were scanned to detect lesion volume and hematoma volume, respectively. Details are described in the online-only Data Supplement.
Brain Water Content Measurement
Water contents were measured at day 3 after ICH, as previously described. 25 In brief, without perfusion, brains were removed from mice and divided into 3 parts: the ipsilateral, the contralateral, and the cerebellum. The brain samples were weighed immediately on an electronic balance to obtain wet weights, then dried for 24 hours at 100°C, and weighed again to obtain dry weights. The following formula was used to calculate the brain water content: (wet weight−dry weight)/wet weight×100%.
Flow Cytometry
To quantify cells expressing NLRP3, microglia (CD11b ) in the brain, we isolated cellular components from brain tissue to perform flow cytometry analysis as we previously described. 23, 26 Details appear in the online-only Data Supplement.
Real-Time Polymerase Chain Reaction
At day 3 after ICH, total RNA was extracted from brain tissue in the ipsilateral hemisphere for real-time polymerase chain reaction analysis as described in the online-only Data Supplement.
Assessment of BBB Permeability
Evans Blue dye (Sigma, St. Louis, MO) extravasation assays were conducted at day 3 after ICH as a tracer to measure BBB permeability, as previously described.
16,27

Western Blots
At day 3 after ICH, Western blots analyzed for NLRP3 inflammasome components and tight junction protein expression in the ipsilateral cerebral hemisphere, as we previously described. 16 Details are given in the online-only Data Supplement.
Statistical Analysis
We determined each sample size by power analysis using a significance level of α=0.05 with 80% power to detect statistical differences. SAS 9.1 software (SAS Institute Inc, Cary, NC) was used for power analysis and sample size calculations. Data were analyzed by investigators blinded to experimental treatments. Data are shown as mean±SD. SPSS 19.0 software was used to compare differences between 2 groups where appropriate. One-way ANOVA followed by the Tukey post hoc test or 2-way ANOVA with multiple comparisons followed by Bonferroni post hoc test was used for comparison of multigroup data. P values <0.05 are considered significant.
Results
MCC950 Attenuates Brain Injury and Improves Long-Term Outcome After ICH
To determine whether the NLRP3 inflammasome inhibitor, MCC950, affects brain injury after ICH, we examined neurodeficits, lesion volume, and perihematomal edema in ICH mice receiving MCC950 or a phosphate-buffered saline vehicle. ICH was induced by injection of autologous blood or collagenase. Mice received MCC950 (10 mg/kg) or vehicle for 3 consecutive days starting immediately after ICH induction ( Figure 1A ). Neurological function was evaluated by using modified Neurological Severity Score and corner-turning tests at days 1 and 3 after ICH. Lesion volume, perihematomal edema, and brain water content were measured at day 3 after ICH. Compared with vehicle recipients, we found that MCC950-treated mice had significantly reduced neurodeficits, lesion volumes, and perihematomal edema after ICH ( Figure 1B and 1C) . MCC950 reduced brain water content after ICH ( Figure I in the online-only Data Supplement). In addition, MCC950 reduces neurodeficits until day 28 after ICH induction ( Figure 1D ), suggesting that NLRP3 inflammasome inhibition can provide long-term benefit after ICH. Of note, the benefit of MCC950 to 
MCC950 Inhibits the Activation of NLRP3 Inflammasome Components and IL-1β Production After ICH
The effect of MCC950 on NLRP3 inflammasome activation and IL-1β production was examined in brain tissues of ICH mice. At day 3 after ICH, we found that MCC950 reduced the mRNA expression of NLRP3 inflammasome components (NLRP3/Caspase-1/ASC) and IL-1β (Figure 2A ). In addition, the protein expression of NLRP3, caspase-1, and IL-1β in the brain was suppressed by MCC950 treatment (Figure 2B and  2C) . Of interest, MCC950 does not affect lipopolysaccharides-induced production IL-1β and TNF-α (tumor necrosis factor-α) from splenocytes ( Figure III in the online-only Data Supplement). These results demonstrate that MCC950 effectively inhibits the activation of NLRP3 inflammasome components and IL-1β production in the brain after ICH.
MCC950 Reduces Leukocyte Infiltration and Production of Proinflammatory Factors by Microglia After ICH
Next, we determined the impact of MCC950 on brain inflammation after ICH. Using flow cytometry, we examined such cellular components as brain-infiltrating leukocytes and microglia in the brains of ICH mice ( Figure 3A Figure 3B and 3C) . Of note, MCC950 reduced the infiltration of CD4 + T cells, CD8 + T cells and neutrophils until day 7 after ICH ( Figure  IV in the online-only Data Supplement). Further, microglia cell numbers decreased as did microglial expression of factor IL-6 ( Figure 3D ). In contrast, the microglial expression of IL-10 and TGF-β (transforming growth factor-β) was increased in ICH mice receiving MCC950 ( Figure 3D ). These results indicate that MCC950 can reduce brain inflammation and cause a shift in microglia phenotype toward an anti-inflammatory status.
MCC950 Preserves BBB Integrity and Reduces Cell Death After ICH
BBB disruption after ICH contributes to vasogenic edema and the expansion of perihematomal edema. 28 To measure the effect of MCC950 on BBB disruption after ICH, we examined Evans Blue dye extravasation and the expression of 
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January 2018 tight junction proteins. At day 3 after ICH, MCC950 significantly ameliorated leakage of the dye ( Figure 4A ), denoting a reduction of BBB permeability. MCC950 also preserved expression of the tight junction proteins (claudin-5 and ZO-1; Figure 4B ). In addition, MCC950 reduced numbers of Annexin V-expressing cells in the brain at day 3 after ICH, suggesting a decrease in cell death ( Figure 4C ). Together, these results demonstrate that MCC950 preserves BBB integrity and reduces cell death after ICH.
Benefit of MCCC950 Against ICH Involves Microglia and Gr-1 + Myeloid Cells
Because microglia are the predominant cell subset expressing NLRP3 inflammasome after ICH ( Figure V in the online-only Data Supplement), we sought to understand to what extent microglia may contribute to the protective effect of MCC950. The survival of microglia depends on signaling through CSF1R (colony-stimulating factor 1 receptor); therefore, we used a CSF1R inhibitor, PLX3397, to deplete microglia before ICH induction ( Figure 5A ). 29 Consistent with our previously described PLX3397 treatment, the present result was a loss of >90% microglia (CD11b + CD45 int ) from mice undergoing ICH. 12 Of interest, we found that the benefit of MCC950 treatment was abolished in ICH mice receiving PLX3397 ( Figure 5B and 5C), suggesting that microglia participate in the beneficial effect of MCC950 after ICH.
Because NLRP3 inflammasome was clearly expressed in Gr-1 + myeloid cells, consisting mainly of neutrophils and monocytes that are known contributors to BBB disruption and brain inflammation, 30, 31 we therefore determined whether Gr-1 + myeloid cells also add to the benefit of MCC950.
An anti-Gr-1 + mAb (RB6-8C5) was used to deplete Gr-1 + myeloid cells from mice before ICH induction ( Figure 6A ). We monitored the counts of Gr-1 + cells in circulating blood at 24 hours before the first injection of anti-Gr-1 mAb and 48 hours after the second injection of anti-Gr-1 mAb ( Figure 6B ). Consistent with a previous report, 32 antiGr-1 + mAb treatment depleted ≈90% of Gr-1 + myeloid cells ( Figure 6B ), that is, mainly neutrophils and monocytes. Of note, the depletion of Gr-1 + myeloid cells diminished the beneficial effects of MCC950 after ICH ( Figure 6C and 6D) , suggesting that the protection of MCC950 also involves Gr-1 + myeloid cells. 
Discussion
This study provides the first evidence that the NLRP3 inflammasome inhibitor, MCC950, attenuates hemorrhagic brain injury. MCC950 significantly reduced neurodeficits and perihematomal edema in 2 mouse models of ICH induced by injection of autologous blood or bacterial collagenase. MCC950 treatment was sufficient to reduce the resulting leukocyte infiltration, microglial production of proinflammatory factors, BBB disruption, and cell death after ICH. In addition, the benefit of MCC950 protection from ICH was diminished in mice subjected to depletion of microglia or Gr-1 + myeloid cells (neutrophils and monocytes). Together, these results suggest that MCC950 has potential therapeutic value for reducing ICH injury.
Mechanistic studies have shown an essential role for the NLRP3 inflammasome in brain injury and neuroinflammation after ICH. [9] [10] [11] The activation of NLRP3 inflammasome facilitates caspase-1 activation and IL-1β processing, leading to the amplification of the inflammatory response, which culminates in the expansion of perihematomal edema, and thereby exacerbating hemorrhagic brain injury. [9] [10] [11] As a small molecule, the NLRP3 inflammasome inhibitor, MCC950, was recently found to selectively inhibit NLRP3 inflammasome formation and reduce pyroptosis and IL-1β signaling. 17 In the present study, our results confirmed the ability of MCC950 to effectively inhibit the activation of NLRP3 inflammasome components and IL-1β production in experimental ICH. In advancing previous findings, 9-11 our study for the first time provides efficacy data depicting pharmacological inhibition by NLRP3 inflammasome in the setting of ICH in vivo.
Other than MCC950, several small molecules inhibit the NLRP3 inflammasome. For example, glyburide inhibited IL-1β production at micromolar concentrations in response to the activation of NLRP3 and was effective in reducing edema formation. 33 Purinergic 2X7 receptor antagonist (blue brilliant G) also diminished NLRP3 inflammasome activation and lessened hemorrhagic brain injury. 34 However, because of the limited potency and nonspecific nature of those agents, the extent to which pharmacologically selective targeting by NLRP3 inflammasome can impact ICH injury is still unclear. However, results from this study provide new evidence that selective NLRP3 inflammasome inhibition offers the benefit of reducing ICH injury and improving long-term outcome, which is an essential step for bringing NLRP3 inflammasometargeted therapies from the bench into clinical application.
Reportedly, NLRP3 might present certain advantages over the use of biological inhibitors of IL-1β. 17 Because MCC950 does not block the major antimicrobial inflammasome NLRC4 or NLRP1, specific targeting of NLRP3 will not result in the complete blockade of IL-1β in vivo, and antimicrobial responses may remain intact. In support of this view, we found that MCC950 does not affect lipopolysaccharides-induced production IL-1β and TNF-α from splenocytes. Considering the immunosuppression that follows stroke, 35 -37 MCC950 may have the advantage of less immunosuppressive effects than biologics such as canakinumab (anti-IL-1β monoclonal antibody), which increased the risk of these infections in a clinical setting. 38, 39 Inflammation of the brain and BBB dysfunction are acknowledged as key contributors to the expansion of perihematomal edema after ICH onset. 4, 28, 40 In that context, we postulate that MCC950 may mitigate the brain's inflammatory milieu to confer protection from the effects of ICH. In support of this view, we found that the benefit of MCC950 treatment was abolished in mice depleted of microglia via a CSF1R inhibitor. That outcome, together with the finding that NLRP3 inflammasome is expressed primarily in microglia after ICH, suggests that the benefit of MCC950 involves its action on microglia. Other than microglia, Gr-1 + myeloid cells (neutrophils and monocytes) also express NLRP3 inflammasome. Of interest, depletion of Gr-1 + myeloid cells using an anti-Gr-1 MAb also diminished the benefit of MCC950. Given the ability of microglia, neutrophils, and monocytes to disrupt the BBB and cause brain edema in ICH, these combined results reinforce the likelihood that the effect of MCC950 on microglia and Gr-1 + myeloid cells contributes to the benefit of MCC950 treatment after ICH. Nevertheless, the precise operating mechanisms by which MCC950 restricts brain inflammation after ICH remains uncertain and requires future investigation.
Conclusions
We have demonstrated that the NLRP3 inflammasome inhibitor, MCC950, attenuates brain injury and inflammation after ICH. Therefore, MCC950 may serve as a promising candidate for further investigation in advanced preclinical ICH studies.
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